Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis

NCT ID: NCT03110198

Last Updated: 2017-04-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 528 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-31
• Study Completion Date: 2018-03-31

Brief Summary

The research aims to evaluate the efficacy and safety of that mesalazine with hydrocortisone sodium succinate for the induction of clinical remission during a 4-week double-blind treatment period in active UC (define as total Mayo score of greater than or equal to 4 and less than or equal to 10). A total of 528 patients will be randomly divided into three group, one will receive mesalazine 4g with hydrocortisone sodium succinate 100mg enema, and the other two group will respectively to receive mesalazine 4g and hydrocortisone sodium 100mg one times daily for 4 weeks. The end of the study for every patient is the improvement of main symptoms.The primary endpoint is the clinical remission after 2 and 4 weeks double-blind treatment, defined on the basis of a total Mayo score ≤ 2 points, with no subscore > 1 point. The secondary endpoint are endoscopic mucosal healing at week 2 and 4 of double-blind period, defined as an absolute subscore for endoscopy portion of the Mayo score of 0 point and the change from baseline in Quality of Life at week 4 of double-blind period based on the IBDQ.

Conditions

Ulcerative Colitis, Unspecified

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Mesalazine with hydrocortisone sodium succinate

Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema

Group Type: EXPERIMENTAL

Mesalazine with hydrocortisone sodium succinate

Intervention Type: DRUG

Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission

Mesalazine

Mesalazine （4g）enema

Group Type: ACTIVE_COMPARATOR

Mesalazine

Intervention Type: DRUG

Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily

Hydrocortisone sodium succinate

Hydrocortisone sodium succinate (100mg ) enema

Group Type: ACTIVE_COMPARATOR

hydrocortisone sodium succinate

Intervention Type: DRUG

hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily

Interventions

Mesalazine

Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily

Intervention Type: DRUG

hydrocortisone sodium succinate

hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily

Intervention Type: DRUG

Mesalazine with hydrocortisone sodium succinate

Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female Chinese patients aged ≥18 to ≤ 70 years

2. Newly diagnosed or recurrent active ulcerative colitis (A gold standard for the diagnosis of ulcerative colitis is not available. The diagnosis should be established by a combination of medical history, clinical evaluation, and typical endoscopic and histological findings. An infective cause should be excluded. Where there is doubt about the diagnosis, endoscopic and histological confirmation is necessary after an interval.)

3. Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy (it should be done within 15 days prior to randomization)

4. Total Mayo score of at least 4 and a score of ≥ 2 for colonoscopy

5. Oralthe stability dose of 5-ASA medicine 14days.

6. Negative stool test at screening to rule out parasites and bacterial pathogens

7. The patient is compliant with Patient Daily Diary

8. Women with childbearing potential must have an efficacious contraception as judged by the investigators and must have a negative pregnancy test result at screening

9. Signed Informed Consent obtained before any trial-related procedures.

Exclusion Criteria

1. Severe/fulminant ulcerative colitis or toxic dilatation of the colon

2. Prior bowel resection surgery

3. Known infection of human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV) (Note active Hepatitis B patients should be excluded from the study e.g. HBeAg positive or HBV DNA positive, with the exception for inactive HBsAg carrier)

4. Take the following treatment:

1. Any 5-ASA enema or suppository therapy during the 14 days prior to screening

2. Corticosteroids (oral, intravenous, intramuscular, or rectal ) within 7 days prior to screening

3. Any immunomodulating/suppressive agents during the 60 days prior to screening

4. Any Anti-TNF therapy during the 6 months prior to screening

5. Antibiotics (metronidazole and ciprofloxacin) within 7 days prior to screening

6. Loperamide, nicotine patch and mucilages within 7 days prior to screening

7. Traditional Chinese Medicine for the treatment of UC (any pharmaceutical form) within 7 days prior to screening

5. Patients allergic to 5-ASA and derivative, any of the excipients, aspirin, or salicylates

6. Known significant hepatic function abnormalities, defined as the values of serum ALT or AST are equal to or more than twice of the upper limit of normal value

7. Women who are planning or actual pregnancy or lactation during study period

8. Alcohol addiction (>40 g of alcohol/day equivalent to >1 L of beer/day, 0.5 L of wine/day, or 6 glasses (2 centiliter, cl) of liquor/day)

9. Drug addiction confirmed by patients' medical history

10. History of disease that would interfere with their participation in the trial, including malignant diseases, bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, and mental or emotional disorder

11. Patient participating or having participated in another clinical study 30 days prior to screening

12. Patient who are unlikely to comply with the protocol as judged by the investigator

13. Patients who are unable to fill in the Patient Daily Diary or follow data-capturing procedures

14. Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease

15. Patients with any other disease or condition which might interfere with study assessment as judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER

Sponsor Role: collaborator

First Affiliated Hospital of Zhongshan Medical University

OTHER

Sponsor Role: collaborator

Xijing Hospital of Digestive Diseases

OTHER

Sponsor Role: lead

Responsible Party

Jie Liang

Associated professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

jie Liang, professor

Role: PRINCIPAL_INVESTIGATOR

China,Shaanxi,Xi'an, Xijing Hospital of Digeetive Disease

Locations

Xijing Digestive Disease

Xi'an, Shaanxi, China

Site Status: RECRUITING

Countries

China

Central Contacts

jie Liang, professor

Role: CONTACT

liangjie@fmmu.edu.cn

86-029-85771535

Facility Contacts

Jie liang, professor

Role: primary

liangjie@fmmu.edu.cn

86-029-84771535

Other Identifiers

KY20162063-1

Identifier Type: -

Identifier Source: org_study_id